TrialBlood advances2022

Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma.

Thomas Martin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.